

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CF PharmTech, Inc.
長風藥業股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2652)

VOLUNTARY ANNOUNCEMENT
VOLUNTARY EXTENSION OF LOCK-UP PERIOD FOR SHARES
HELD BY CORE MANAGEMENT BY SIX MONTHS

This announcement is made by CF PharmTech, Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the latest development of the Company.

Reference is made to the prospectus dated September 26, 2025 (the “**Prospectus**”) and the announcement on allotment results dated October 6, 2025 (the “**Allotment Results Announcement**”) issued by the Company. Unless otherwise defined, capitalised terms used in this announcement shall have the same meanings as those defined in the Prospectus and the Allotment Results Announcement. The H Shares of the Company were listed on the Main Board of The Stock Exchange of Hong Kong Limited on October 8, 2025 (the “**Listing Date**”). As disclosed in the Allotment Results Announcement, pursuant to the PRC Company Law, the shares issued by the Company prior to its listing are subject to lock-up restrictions for a period of twelve months from the Listing Date, and such lock-up period (the “**Original Lock-up Period**”) will expire on October 7, 2026.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that the Company has recently received voluntary undertakings (the “**Undertakings**”) made by Dr. LIANG Bill Wenqing, the co-founder, chairperson of the Board, executive Director and chief executive officer of the Company, and Dr. LI LI BOVET, the co-founder, executive Director and chief scientific officer of the Company (collectively, the “**Core Management**”) based on their confidence in the long-term development prospects and long-term value of the Group. Pursuant to the Undertakings, the Core Management have voluntarily undertaken to further extend the lock-up period in respect of the shares of the Company in which they are directly or indirectly beneficially interested (the “**Relevant Shares**”) by six months upon the expiry of the Original Lock-up Period (the “**Extended Lock-up Period**”). The Extended Lock-up Period shall commence on October 8, 2026 and expire on April 7, 2027 (both dates inclusive).

The Relevant Shares comprise: (1) 15,677,427 H Shares and 10,451,618 Unlisted Shares held by Dr. LIANG Bill Wenqing through Suzhou Pyramid Investment Management Enterprise (Limited Partnership) (蘇州嶺頭投資管理企業(有限合夥)) (“**Suzhou Pyramid**”), which is controlled by him; (2) 14,378,728 H Shares and 9,585,819 Unlisted Shares held by Dr. LI LI BOVET through Suzhou Meizhongrui Investment Management Enterprise (Limited Partnership) (蘇州美中瑞投資管理企業(有限合夥)) (“**Suzhou Meizhongrui**”), which is controlled by her; and (3) an aggregate of 7,563,276 shares in which Dr. LIANG Bill Wenqing and Dr. LI LI BOVET have interests in the employee incentive platforms of the Company through Suzhou Pyramid and Suzhou Meizhongrui, respectively (such shares do not form part of the 2024 share incentive scheme of the Company).

For the avoidance of doubt, the shares held by Suzhou Minmei Investment Management Enterprise (Limited Partnership) (蘇州閩美投資管理企業(有限合夥)), Suzhou Yuanchen Enterprise Management Center (Limited Partnership) (蘇州遠辰企業管理中心(有限合夥)), Suzhou Wolun Enterprise Management Center (Limited Partnership) (蘇州沃倫企業管理中心(有限合夥)), Suzhou Yuansheng Enterprise Management Partnership (Limited Partnership) (蘇州遠昇企業管理合夥企業(有限合夥)) and Suzhou Dacheng Enterprise Management Partnership (Limited Partnership) (蘇州達辰企業管理合夥企業(有限合夥)) for the implementation of the 2024 share incentive scheme of the Company do not constitute the Relevant Shares and are not subject to the lock-up restrictions under the Undertakings.

During the Extended Lock-up Period, the Core Management undertake not to, directly or indirectly, sell, transfer, dispose of or otherwise reduce their holdings in any of the Relevant Shares, except as permitted by applicable laws and regulations or the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”).

The Company believes that the voluntary Undertakings made by the Core Management are based on their confidence in the long-term development strategies, business prospects and continuous value creation capabilities of the Group, and demonstrate their commitment to aligning their interests with the long-term interests of the Company and the shareholders as a whole. The Undertakings are made voluntarily and without consideration by the Core Management.

The above Undertakings do not replace or derogate from any other restrictions which the Core Management are required to comply with under applicable laws and regulations, the Listing Rules, the Model Code for Securities Transactions by Directors of Listed Issuers as set out in Appendix C3 to the Listing Rules, and the relevant internal policies of the Company.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
CF PharmTech, Inc.
長風藥業股份有限公司
Dr. LIANG Bill Wenqing

Chairperson, Executive Director and Chief Executive Officer

Hong Kong, October 5, 2026

As at the date of this announcement, the Board comprises Dr. LIANG Bill Wenqing, Dr. LI LI BOVET, Dr. LI Qi, Ms. ZHU Yuyu and Ms. ZHANG Jingjing as executive Directors, Mr. CAI Lei and Dr. YI Hua as non-executive Directors, and Dr. JIN Jian, Ms. WANG Lijuan, Mr. WEI Shirong and Mr. IP Wang Hoi as independent non-executive Directors.